📇 Rhumatologue · BRON CEDEX · (69) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Plateau technique de référence
Hospices Civils de Lyon (HCL) — équipements et expertise pointus pour les cas complexes
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
HOPITAL PIERRE WERTHEIMER - HCL
59 BD PINEL, 69677 BRON CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · 2025
Purpose To compare patient‐reported outcomes, complications, and revision rates after the use of autograft versus allograft for primary arthroscopic hip labral reconstruction. Methods The PubMed, Scopus, and Embase databases were queried following the 2020 Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines to identify human clinical studies reporting outcomes following primary arthroscopic hip labral reconstruction with a minimum follow‐up of 2 years. Studies that did not report graft type or outcomes were excluded. Studies were separated into 2 cohorts on the basis of graft type, allograft or autograft. The mean delta (change from preoperative to postoperative values) was calculated for each patient‐reported outcome score and compared between cohorts. The methodological index for non‐randomized studies criteria were used to evaluate bias. Results Seventeen studies (allograft = 9 studies, autograft = 11 studies) of 756 patients were included. Mean follow‐up for the allograft cohort was 37 months (mean range, 25.5‐66.1) compared with 38.3 months (mean range, 25.4‐80.8) for the autograft cohort. At final follow‐up, delta values for modified Harris Hip Score ranged from 18.2‐34 (allograft) versus 9.4‐31.7 (autograft), HOS‐Sports scale ranged from 24.2‐39.7 (allograft) versus 21.4‐41.3 (autograft), visual analog pain scale ranged from −5.7 to −1.7 (allograft) versus −5.7 to −2.4 (autograft), and delta values for the Non‐Arthritic Hip score ranged from 19.7‐31.3 (allograft) versus 16.6‐35.4 (autograft). Postoperative complication rates ranged from 0.0% to 17.6% (allograft) versus 0.0% to 9.1% (autograft). The most common complication for the allograft cohort was numbness (n = 2) versus heterotopic ossification (n = 6) in the autograft cohort. Rates of arthroscopic revision surgery were 0.0% to 5.9% (allograft) versus 0.0% to 9.1% (autograft), whereas conversion to total hip arthroplasty ranged from 0.0% to 17.6% (allograft) versus 0.0% to 8.3% (autograft). Conclusions The use of allografts and autografts in primary hip labral reconstruction results in improved postoperative outcomes. However, allografts were associated with greater rates of complications with worse graft survivorship. Level of Evidence Level IV, systematic review of Level of Evidence III‐IV studies.
Journal of clinical medicine · 2025
Background/Objectives: GPA is a PR3-ANCA–predominant small vessel vasculitis with organ involvement. Real-world, single-centre data are needed to interpret evolving therapies and phenotype patterns in national conditions. Material and Methods: Retrospective cohort study of consecutive GPA patients managed at the National Institute of Geriatrics, Rheumatology and Rehabilitation (Warsaw, Poland) from 1 September 2010 to 1 September 2025. Data included demographics, phenotype, BVAS, organ involvement, PR3/MPO-ANCA serology, and induction/maintenance therapies. Results: Fifty patients were included (54.0% men). Mean age was 52.5 years; mean BMI was 26.15 kg/m2. Ear-nose-throat (ENT) disease was frequent: rhinosinusitis 76.0%, nasal cartilage destruction 64.0%, subglottic stenosis 34.0%. Pulmonary nodules occurred in 52.0%, cavitation in 28.0%, and diffuse alveolar haemorrhage in 34.0%. Renal involvement included haematuria in 42.0%, chronic kidney disease (CKD) in 32.0%, and rapidly progressive kidney disease in 22.0%. Orbital inflammation was 36.0%, and PR3-ANCA was positive in 70.0%. All patients received glucocorticoids for induction; cyclophosphamide 28/50 (56.0%), rituximab 6/50 (12.0%), and mycophenolate with methotrexate 6/50 (32%). Maintenance therapy included methotrexate (78.0%), mycophenolate (64.0%), rituximab (52.0%), and azathioprine (12.0%). Conclusions: This Polish single-centre cohort shows an ear-nose-throat-lung-kidney (ELK)-dominant, PR3-predominant GPA phenotype and frequent but variable kidney involvement. Over 2010–2025, practice changed toward rituximab-based strategies, steroid minimisation, selective use of plasma exchange, and early avacopan uptake, with tofacitinib for maintenance therapy as a possible new therapeutic option.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · 2025 · Comparative Study
Mowers CC, Childers JT, Lack BT, Hus AS, et al.
Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · 2025 · Comparative Study
Mowers CC, Childers JT, Lack BT, Hus AS, et al.
Journal of clinical medicine · 2025 · Journal Article
Hus A, Kanecki K, Lewtak K, Goryński P, et al.
Journal of clinical medicine · 2025 · Journal Article
Hus A, Wisłowska M, Bonek K